TY - JOUR T1 - <em>CRY1</em> Regulates Chemoresistance in Association With <em>NANOG</em> by Inhibiting Apoptosis <em>via STAT3</em> Pathway in Patients With Cervical Cancer JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 699 LP - 713 DO - 10.21873/cgp.20291 VL - 18 IS - 6 AU - GWAN HEE HAN AU - JULIE KIM AU - HEE YUN AU - HANBYOUL CHO AU - JOON-YONG CHUNG AU - JAE-HOON KIM AU - STEPHEN M. HEWITT Y1 - 2021/11/01 UR - http://cgp.iiarjournals.org/content/18/6/699.abstract N2 - Background/Aim: Cryptochrome 1 (CRY1), a core circadian gene, modulates circadian rhythm and carcinogenesis. Here, we investigated the role of CRY1 and its correlation with NANOG, a stem cell transcription factor, in cervical cancer. Materials and Methods: Immunohistochemistry with tissue microarray was performed to evaluate CRY1 and NANOG expression in cervical cancer tissues, and their functional roles were assessed in cervical cancer cell lines. Results: CRY1 or NANOG was significantly over-expressed in cervical cancer tissues. Notably, combined over-expression of CRY1 and NANOG was correlated with a significantly poor OS and DFS and showed a stronger predictive value for chemoradiation response than each single protein. Furthermore, siCRY1 induced apoptosis, decreased NANOG expression, suppressed STAT3 signalling, and activated p53 signalling in cervical cancer cell lines. Conclusion: CRY1 and NANOG over-expression serves as a strong predictive biomarker for prognosis and chemoradiation response, and may be a new therapeutic target in patients with cervical cancer. ER -